Serum levels of 3α-androstanediol glucuronide in hirsute and non hirsute women

European Journal of Endocrinology

Volumn 138, Issue 4, 1998, Pages 421-424

  Falsetti, L ^a,b   Rosina, B ^a   De Fusco, D ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANE DERIVATIVE; ANDROSTANEDIOL; ANDROSTANE 3,17 DIOL GLUCURONIDE; ANDROSTANE-3,17-DIOL GLUCURONIDE; DRUG DERIVATIVE;

ADOLESCENT; ADULT; ANDROGEN SYNTHESIS; ARTICLE; BLOOD LEVEL; FEMALE; HIRSUTISM; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; SCORING SYSTEM; BLOOD; CASE CONTROL STUDY; HYPERANDROGENISM; OBESITY;

ADOLESCENT; ADULT; ANDROSTANE-3,17-DIOL; CASE-CONTROL STUDIES; FEMALE; HIRSUTISM; HUMANS; HYPERANDROGENISM; OBESITY; POLYCYSTIC OVARY SYNDROME;

EID: 0031596548     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1380421     Document Type: Article

References (23)

1. Knocherhauer ES & Azziz R. Advances in the diagnosis and treatment of the hirsute patients. Current Opinion in Obstetrics and Gynecology 1995 7 344-350.
2. Barbieri RL. Hyperandrogenic disorders. Clinical Obstetrics and Gynecology 1990 33 640-654.
3. Maroulis GB. Evaluation of hirsutism and hyperandrogenemia. Fertility and Sterility 1981 273-305.
4. Rittmaster RS & Loriaux DL. Hirsutism. Annals of Internal Medicine 1987 106 95-99.
5. Hatch R, Rosenfield RL, Kim MH & Tredway D. Hirsutism: implications and etiology and management. American Journal of Obstetrics and Gynecology 1981 140 815-830.
6. Goldzieher JW & Axelrod IR. Clinical and biochemical features of polycystic ovarian disease. Fertility and Sterility 1963 14 631-653.
7. Stewart PM, Shackleton CHL, Beastall GH & Edwards CRW. 5α-Reductase activity in polycystic ovary syndrome. Lancet 1990 335 431-433.
8. Lobo RA, Goebelrmann U & Horton R. Evidence for the importance of peripheral tissue events in the development of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 1983 57 393-397.
9. Serafini PC & Lobo RA. Increased 5 alpha-reductase activity in idiopathic hirsutism. Fertility and Sterility 1985 43 74-78.
10. Kutten F, Mowszowicz I, Schaison G & Mauvais-Jarvis P. Androgen production and skin metabolism in hirsutism. Journal of Endocrinology 1977 75 83-89.
11. Horton R, Hawks D & Lobo R. 3 alpha- and 17 beta-androstanediol glucuronide in plasma: a marker of androgen action in idiopathic hirsutism. Journal of Clinical Investigation 1982 62 1203-1206.
12. Carmina E, Stanczyk FZ, Gentzchein E & Lobo R. Time-dependent changes in serum 3α-androstanediol glucuronide correlate with hirsutism scores after ovarian suppression. Gynecological Endocrinology 1995 9 215-220.
13. Horton R & Lobo R. Peripheral androgens and the role of androstanediol glucuronide. Journal of Clinical Endocrinology and Metabolism 1986 15 293-306.
14. Giagulli VA, Verdnock L, Deslypere JP, Giorgino R & Vermeulen A. Comparison of plasma androgen glucuronide levels after percutaneous or peroral androgen treatment in men: evidence for important splanchnic contribution to plasma 17 beta-hydroxyandrogen glucuronides. Journal of Clinical Endocrinology and Metabolism 1993 76 429-431.
15. Rittmaster RS. Androgen conjugates: physiology and clinical significance. Endocrine Reviews 1993 14 121-132.
16. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979 28 1039-1057.
17. Ferriman D & Gallway JD. Clinical assessment of body hair growth in women. Journal of Clinical Endocrinology and Metabolism 1961 21 1440-1448.
18. Cassidenti DL, Paulson RJ, Serafini P, Stanczyk FZ & Lobo AR. Effects of sex steroids on skin 5α-reductase activity in vitro. Obstetrics and Gynaecology 1991 78 103-107.
19. Jahanfar S, Eden JA, Warren P, Seppala M & Nguyen TV. A twin study of polycystic ovary syndrome. Fertility and Sterility 1995 63 478-486.
20. Lobo RA. Hirsutism in polycystic ovary syndrome: current concepts. Clinical Obstetrics and Gynecology 1991 34 817-826.
21. Paulson RJ, Serafini PC, Catalino JA & Lobo RA. Measurements of 3 alpha, 17 beta-androstanediol glucuronide in serum and urine and the correlation with the skin 5 alpha-reductase activity. Fertility and Sterility 1986 46 222-226.
22. Lobo RA, Paul WL, Gentzschein E, Serafini PC, Catalino JA & Paulson RJ. Production of 3 alpha-androstanediol glucuronide in human genital skin. Journal of Clinical Endocrinology and Metabolism 1987 65 711-714.
23. Duffy DM, Legro RS, Chang L, Stanczyk FZ & Lobo R. Metabolism of dihydrotestosterone to 5 alpha-androstane-3 alpha, 17 beta-diol glucuronide is greater in the peripheral compartment than in the splanchnic compartment. Fertility and Sterility 1995 64 736-739.